Unhealthy pharmaceutical regulation : innovation, politics and promissory science /Courtney Davis and John Abraham

Abraham, John 1961-
Публикация
Houndmills : Palgrave Macmillan , 2013
Физическое описание
XII, 321 p.: ill.
Электронный ресурс
Другой Автор
Davis, Courtney 1965-
Содержание
Machine generated contents note: Introduction -- Innovation, Therapeutic Progress and Regulation -- The Regulatory Culture of Accelerated Drug Development and Review -- Regulatory and Scientific Standards -- Reshaping the Evidence-Base -- Risk Management Versus Market Withdrawal -- Rapid Regulatory Review, Pharmaceutical Innovation and Public Health -- Transparency, Public Accountability and Meeting Patients' Needs -- Conclusion -- References/Bibliography -- Index.
Серия
Health, technology and society
Аннотация
"European and American drug regulators govern a multi-billion-dollar pharmaceutical industry selling its products on the world's two largest medicines markets. This is the first book to investigate how effectively American and supranational EU governments have regulated innovative pharmaceuticals regarding public health during the neo-liberal era of the last 30 years. Drawing on years of fieldwork, the authors demonstrate that pharmaceutical regulation and innovation have been misdirected by commercial interests and misconceived ideologies, which induced a deregulatory political culture contrary to health interests. They dismantle the myth that pharmaceutical innovations necessarily equate with therapeutic advances and explain how it has been perpetuated in the interests of industry by corporate bias within the regulatory state, unwarranted expectations of promissory science, and the emergent patient-industry complex. Endemic across both continents, the misadventures of pharmaceutical deregulation are shown to span many therapeutic areas, including cancer, diabetes and irritable bowel syndrome. The authors propose political changes needed to redirect pharmaceutical regulation in the interests of health. "--
Всего оценка: 0
Место хранения Расст.шифр Части Штрих-код Класс экземпляра Примечание Код коллекции Статус  
Факультетская библиотека
С550.47 A16
13820000946249
Выдается в читальный зал
НОЦ "Центр соц.-полит. исследований техн."
 
 
 
04221cam a2200601 c 4500
001
 
 
vtls000565038
003
 
 
RU-ToGU
005
 
 
20170426181000.0
008
 
 
170316s2013    enka   f b    001 0 eng 
020
$a 9780230008663
020
$a 0230008666
035
$a to000565038
039
9
$a 201704261810 $b cat34 $c 201703231007 $d cat07 $c 201703201413 $d cat34 $y 201703161355 $z cat34
040
$a DLC $b eng $c DLC $e rda $d DLC $d RU-ToGU
042
$a pcc
043
$a n-us--- $a e------
050
0
0
$a RA401.A1 $b A27 2013
082
0
0
$a 362.17/82 $2 23
084
$a С550.54 $2 rubbk
100
1
$a Abraham, John $d 1961-
245
1
0
$a Unhealthy pharmaceutical regulation $b innovation, politics and promissory science $c Courtney Davis and John Abraham
260
$a Houndmills $b Palgrave Macmillan $c 2013
300
$a XII, 321 p. $b ill.
336
$a text $2 rdacontent
337
$a unmediated $2 rdamedia
338
$a volume $2 rdacarrier
490
1
$a Health, technology and society
504
$a Bibliogr.: p. 292-316
504
$a Index: p. 317-321
505
8
$a Machine generated contents note: Introduction -- Innovation, Therapeutic Progress and Regulation -- The Regulatory Culture of Accelerated Drug Development and Review -- Regulatory and Scientific Standards -- Reshaping the Evidence-Base -- Risk Management Versus Market Withdrawal -- Rapid Regulatory Review, Pharmaceutical Innovation and Public Health -- Transparency, Public Accountability and Meeting Patients' Needs -- Conclusion -- References/Bibliography -- Index.
520
$a "European and American drug regulators govern a multi-billion-dollar pharmaceutical industry selling its products on the world's two largest medicines markets. This is the first book to investigate how effectively American and supranational EU governments have regulated innovative pharmaceuticals regarding public health during the neo-liberal era of the last 30 years. Drawing on years of fieldwork, the authors demonstrate that pharmaceutical regulation and innovation have been misdirected by commercial interests and misconceived ideologies, which induced a deregulatory political culture contrary to health interests. They dismantle the myth that pharmaceutical innovations necessarily equate with therapeutic advances and explain how it has been perpetuated in the interests of industry by corporate bias within the regulatory state, unwarranted expectations of promissory science, and the emergent patient-industry complex. Endemic across both continents, the misadventures of pharmaceutical deregulation are shown to span many therapeutic areas, including cancer, diabetes and irritable bowel syndrome. The authors propose political changes needed to redirect pharmaceutical regulation in the interests of health. "-- $c Provided by publisher.
650
0
$a Pharmaceutical policy $z United States.
650
0
$a Pharmaceutical policy $z European Union countries.
650
0
$a Drugs $x Law and legislation $z United States.
650
0
$a Drugs $x Law and legislation $z European Union countries.
650
0
$a Pharmaceutical industry $x Political aspects.
650
7
$a SOCIAL SCIENCE / Sociology / General. $2 bisacsh
650
7
$a SOCIAL SCIENCE / Disease & Health Issues. $2 bisacsh
650
7
$a POLITICAL SCIENCE / Public Policy / General. $2 bisacsh
650
7
$a MEDICAL / Health Policy. $2 bisacsh
650
7
$a MEDICAL / Pharmacy. $2 bisacsh
653
$a фармацевтическая промышленность.
653
$a фармацевтическая политика
653
$a США
653
$a страны Европейского Союза
653
$a лекарственные средства
653
$a здравоохранение.
700
1
$a Davis, Courtney $d 1965-
830
0
$a Health, technology and society
852
4
$a RU-ToGU $h С550.47 $i A16 $n ru
856
4
2
$3 Cover image $u http://www.netread.com/jcusers2/bk1388/663/9780230008663/image/lgcover.9780230008663.jpg
999
$a VIRTUA
999
$a VTLSSORT0080*0200*0201*0350*0400*0420*0430*0500*0820*0840*1000*2450*2600*3000*3360*3370*3380*4900*5040*5041*5050*5200*6500*6501*6502*6503*6504*6505*6506*6507*6508*6509*6530*6531*6532*6533*6534*6535*7000*8300*8520*8560*9992
Нет комментариев.
Предмет
Pharmaceutical policy United States.
Pharmaceutical policy European Union countries.
Drugs Law and legislation United States.
Drugs Law and legislation European Union countries.
Pharmaceutical industry Political aspects.
SOCIAL SCIENCE / Sociology / General.
SOCIAL SCIENCE / Disease & Health Issues.
POLITICAL SCIENCE / Public Policy / General.
MEDICAL / Health Policy.
MEDICAL / Pharmacy.
Резюме
"European and American drug regulators govern a multi-billion-dollar pharmaceutical industry selling its products on the world's two largest medicines markets. This is the first book to investigate how effectively American and supranational EU governments have regulated innovative pharmaceuticals regarding public health during the neo-liberal era of the last 30 years. Drawing on years of fieldwork, the authors demonstrate that pharmaceutical regulation and innovation have been misdirected by commercial interests and misconceived ideologies, which induced a deregulatory political culture contrary to health interests. They dismantle the myth that pharmaceutical innovations necessarily equate with therapeutic advances and explain how it has been perpetuated in the interests of industry by corporate bias within the regulatory state, unwarranted expectations of promissory science, and the emergent patient-industry complex. Endemic across both continents, the misadventures of pharmaceutical deregulation are shown to span many therapeutic areas, including cancer, diabetes and irritable bowel syndrome. The authors propose political changes needed to redirect pharmaceutical regulation in the interests of health. "--